Open AccessEffect of percutaneous radiofrequency ablation after thoracoscopic pleurodesis for treating non‐small cell lung cancer patients with malignant pleural effusion and/or pleural dissemination
Author(s) -
Liu Baodong,
Liu Lei,
Hu Mu,
Qian Kun,
Li Yuanbo
Publication year - 2016
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12367
Subject(s) - medicine , malignant pleural effusion , pleural effusion , thoracoscopy , pleurodesis , radiofrequency ablation , lung cancer , percutaneous , surgery , mesothelioma , pleural disease , lung , radiology , ablation , respiratory disease , pathology
Background The purpose of this study was to retrospectively evaluate percutaneous radiofrequency ablation ( RFA ) combined with palliative thoracoscopic pleurodesis ( TP ) for malignant pleural effusion and/or pleural disseminated non‐small cell lung cancer ( NSCLC ), diagnosed by thoracoscopy. Methods The study was composed of 40 patients with primary NSCLC with malignant pleural effusion and/or pleural dissemination recognized for the first time during thoracoscopic exploration. Twenty patients received TPR ( TP plus RFA group), while the remaining 20 patients who underwent TP ( TP group) represented the control. We evaluated technical success, safety, initial response rate, progression‐free survival ( PFS ), and overall survival ( OS ). Results No procedure‐related deaths or major complications occurred in any of the 22 ablation procedures. Complete response was observed in 15% of patients, partial response in 50%, stable disease in 25%, and progressive disease in 15% of patients. The mean follow‐up was 15.5 months. The PFS at years one, two, and three were 77.5%, 38.8%, and 25.8%, respectively. The OS at years one, two, and three were 77.5%, 41.4%, and 27.6%, respectively. The PFS and OS were longer in the TP‐R group, indicating a better prognosis than that of the patients who underwent TP only ( OS 24 vs. 18 months, P = 0.030; PFS 22 vs. 15 months, P = 0.036). Conclusions Palliative TP combined with percutaneous RFA is a safe, feasible, and effective procedure in patients with malignant pleural effusion and/or pleural disseminated NSCLC .